July, 2026
What we've learned about execution in cell and gene therapy trials
Cell and gene therapy (CGT) has already transformed the scientific landscape of clinical development.
Now it’s transforming the operational one.
As more therapies move through development and toward commercialization, execution is becoming just as important as scientific innovation itself. Clinical trial logistics, compliance, packaging, storage, and supply chain coordination all play a direct role in whether therapies successfully reach patients.
Across the industry, several clear lessons are emerging.
The patient pathway now drives the clinical trial supply chain
Traditional clinical trial supply chain models were built around inventory movement, forecast demand, and operational flexibility.
CGT operates differently.
Patient material may need to be collected, transported for manufacturing, processed under tightly controlled conditions, and returned for administration within narrow treatment windows.
As a result, the clinical trial supply chain is shaped around the patient timeline rather than product availability alone.
For CGT supply chain management teams, success depends on maintaining coordination across clinical trial logistics, manufacturing, storage, and clinical operations from end to end.
Time has become part of the treatment pathway
Many CGT therapies operate within highly time-sensitive windows. Once a product is released, there may be only hours available for transportation, site preparation, administration, and patient treatment.
That creates significant pressure across:
- Clinical trial logistics management
- Clinical trial distribution Investigational
- Medicinal Product (IMP) distribution
- Global cell therapy distribution
In this environment, delays can affect product viability, patient treatment timelines, and clinical trial continuity. Time now directly influences how reliably the treatment pathway can operate.
Compliance and execution now move together
As CGT pathways become more interconnected, compliance activities must align with operational timelines in real time.
This includes:
- Clinical trial compliance
- Clinical trial regulatory management
- QP release for clinical trial products
- QP batch release
- Supply chain regulatory compliance
- Pharmaceutical compliance and regulation
For global trials, additional layers of pharmaceutical regulation, import requirements, labeling regulations, and documentation processes further increase complexity.
The industry is increasingly moving toward operational models where compliance is embedded directly into the execution pathway rather than managed separately from it.
Packing, storage and labeling have become strategic execution functions
Packaging and storage decisions can directly affect whether therapies remain viable throughout the clinical trial supply chain.
That has elevated the importance of:
- Clinical trial cold chain packaging
- Cold chain packaging solutions
- Temperature controlled pharmaceutical storage
- Specialized cryogenic storage
- Cryostorage for cell therapies
- Clinical trial storage solutions
The same applies to clinical trial labeling and labeling compliance requirements.
Secondary package labeling, certified labeling solutions, and all temperature package labeling all contribute to safe and compliant movement across highly time-sensitive pathways.
Even relatively small packaging or labeling issues can create disruption across the wider system.
High-performing execution depends on connected partnerships
CGT execution increasingly depends on multiple organizations functioning as one connected ecosystem.
Clinical trial logistics companies, manufacturing partners, regulatory specialists, packaging teams, storage providers, and clinical operations groups all play interconnected roles across the pathway.
This is particularly important across:
- Clinical trial logistics
- Cell and gene therapy logistics
- Clinical supply chain management
- Pharmaceutical distribution supply chain coordination
- Cold chain pharmaceutical distribution
For many organizations, the focus is shifting away from isolated outsourcing models toward integrated operational partnerships that improve visibility, coordination, and execution reliability.
The future of CGT will be shaped by operational maturity
The science behind CGT continues to evolve rapidly.
But future progress will depend just as heavily on operational maturity.
Across the industry, organizations are investing in:
- Earlier operational planning Integrated delivery models
- Greater real-time visibility
- Smarter clinical supply chain management
- Harmonized global regulatory strategies
- Scalable clinical trial logistics management systems
The direction of travel is becoming increasingly clear.
Breakthrough therapies alone will not define the next generation of leaders in CGT.
Success will depend on the ability to deliver those therapies reliably across increasingly complex, regulated, and time-sensitive pathways.
For clinical development leaders, scientific readiness is now only part of the challenge.
It’s whether the operational model supporting it is ready too.
